Veraxa Biotech presents in vivo proof — of — concept data for BiTAC — ADC platform at World ADC Congress
Veraxa Biotech AG presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC Congress. Data showed the dual-component approach drove tumor shrinkage in an animal cancer model following systemic dosing. Non-targeted dosing configurations produced no meaningful anti-tumor effect, supporting